Novartis appoints Federico Mambretti as new Country President in Belgium and Luxembourg

Novartis has appointed Federico Mambretti as Country President of Novartis Belgium and Luxembourg. He will bring his years of experience in the healthcare industry as well as his international background to further strengthen Novartis' more than 100-year-old innovation footprint in Belgium. In his role as Country President, Novartis’ research activities – currently leading the country with 150 clinical studies – will take center stage. Similarly, the production site for highly specialized eye medicine in Puurs will also play an important role. One of Mambretti’s ambitions is to accelerate and broaden access to innovative medicines. In this respect, dialogue and cooperation with all stakeholders in the healthcare ecosystem will be essential. With its many innovations, Novartis makes an important social contribution that goes beyond just the health of the population. When someone with a serious illness can continue to work and live a full social life thanks to appropriate treatment, this positive impact extends to the person's well-being and the country's prosperity. In addition to its scientific and social impact, Novartis has an economic impact, providing 5,308 jobs (incl. indirect jobs) in Belgium and contributing some 600 million euros to Belgium’s GNP. (1)

Further embedding the Novartis innovation footprint in Belgium

"I am really looking forward to representing Novartis in Belgium and Luxembourg and making a positive contribution to patients' lives together with our 2,000 employees. Advancing science and access to innovation is both the opportunity and the challenge of the next decade. By working closely together across the health ecosystem, we can ensure that cardiovascular disease takes fewer lives, eyes continue to see, inflammation of the skin and joints does not interfere with quality of life, people with cancer continue to live the best possible lives, and patients live longer because we can reprogram cells. In my new role, I will be particularly committed to accelerating patient access to our innovative medicines and maintaining our leadership in clinical trials. I also want to ensure that we can continue to invest in our manufacturing site in Puurs, where a large part of our medicines for eye diseases is produced, 'Made in Belgium' for distribution to patients in more than 155 countries," said Federico Mambretti, Country President of Novartis in Belgium & Luxembourg.

Together, let’s make some devastating diseases a thing of the past

"At Novartis, we are committed to reimagining medicines and innovating the way patients access innovation. We do this, on the one hand, with one of the most extensive pipelines in the industry, a unique portfolio of innovative medicines, advanced technology platforms and near-term launches in more than 10 therapeutic areas. On the other hand, with our Sandoz generic and biosimilar medicines, we ensure that we fund innovation in a sustainable way. I am convinced that by working closely together, we can make some diseases a thing of the past. The power for this lies in our employees, who are driven by inspiration and curiosity in an 'unbossed' environment. They also choose where and when they work to make a lasting impact for patients," he continues.

Short biography of Federico Mambretti

Federico Mambretti has almost 20 years of experience in the pharmaceutical and healthcare industry. He is Italian and has worked in 10 countries. He joined Novartis in 2012 where he started as Global Director Strategy at Sandoz, Novartis’ generic and biosimilar division. In 2021, he moved with his wife and two daughters to Belgium, where he assumed the role of Country Pharma Organization Head in September, and since February 2022, he has also been responsible for Novartis BeLux as Country President. He succeeds Guy Oliver who returns to the UK at the end of February to pursue his career outside of Novartis.